Enhanced topoisomerase I activity and increased topoisomerase IIα content in cisplatin-resistant cancer cell lines

Japanese Journal of Cancer Research

Volumn 88, Issue 12, 1997, Pages 1218-1223

  Minagawa, Yukihisa ^a   Kigawa, Junzo ^a   Irie, Takashi ^a   Kanamori, Yasunobu ^a   Itamochi, Hiroaki ^a   Cheng, Xiusi ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Cancer cells; Cisplatin; Drug resistance; Topoisomerase I; Topoisomerase II

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 0031460718     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00352.x     Document Type: Article

References (28)

1. Loehrer, P. J. and Einhorn, L. H. Drugs five years later. Cisplatin. Ann. Intern. Med., 100, 704-713 (1984).
2. Ozols, R. F. and Young, R. C. Chemotherapy of ovarian cancer. Sem. Oncol., 11, 251-263 (1984).
3. Scanlon, K. J., Kashani-Sabet, M., Miyachi, H., Sowers, L. C. and Rossi, J. Molecular basis of cisplatin resistance in human carcinomas; model systems and patients. Anticancer Res., 9, 1301-1312 (1989).
4. Andrews, P. A. and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43 (1990).
5. Drlica, K. and Franco, R. J. Inhibitors of DNA topoisomerases. Biochemistry, 27, 2253-2259 (1988).
6. Cain, J. M., Collins, C., Petersdorf, S., Figge, D. C., Tamimi, H. K., Greer, B. E. and Livingston, R. B. Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Am. J. Obstet. Gynecol., 174, 1688-1694 (1996).
7. Zanaboni, F., Scarfone, G., Presti, M., Maggi, R., Borello, C. and Bolis, G. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. Gynecol. Oncol., 43, 24-28 (1991).
8. Fujiwara, Y., Sugimoto, Y., Kasahara, K., Bungo, M., Yamakido, M., Tew, K. D. and Saijo, N. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn. J. Cancer Res., 81, 527-535 (1990).
9. Hertzberg, R. P., Caranfa, M. J. and Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28, 4629-4638 (1989).
10. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
11. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K. and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol., 10, 1775-1780 (1992).
12. Minagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H. and Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res., 85, 966-971 (1994).
13. Kikuchi, Y., Miyauchi, M., Kizawa, I., Oomori, K. and Kato, K. Establishment of cisplatin-resistant human ovarian cancer cell line. J. Natl. Cancer Inst., 77, 1181-1185 (1986).
14. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
15. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S. and Miura, Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50, 604-610 (1992).
16. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 12, 248-254 (1976).
17. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
18. Crespi, M. D., Ivanier, S. E., Genovese, J. and Baldi, A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem. Biophys. Res. Commun., 136, 521-528 (1986).
19. Liu, L. F. and Miller, K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa nuclei. Proc. Natl. Acad. Sci. USA, 78, 3487-3491 (1981).
20. Marini, J. C., Miller, K. G. and Englund, P. T. Decatenation of kinetoplast DNA by topoisomerases. J. Biol. Chem., 255, 4976-4979 (1980).
21. Miller, K. G., Liu. L. F. and Englund, P. T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J. Biol. Chem., 256, 9334-9339 (1981).
22. Kotoh, S., Naito, S., Yokomizo, A., Kumazawa, J., Asakuno, K., Kohno, K. and Kuwano, M. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res., 54, 3248-3252 (1994).
23. Fukuda, M., Nishio, K., Kanazawa, F., Ogasawara, H., Ishida, T., Arioka, H., Bojanowski, K., Oka, M. and Saijo, N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res., 56, 789-793 (1996).
24. van der Zee, A. G. J., de Jong, S., Keith, W. N., Hollema, H., Boonstra, H. and de Vries, E. G. E. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res., 54, 749-755 (1994).
25. de Jong, S., Timmer-Bosscha, H., de Vries, E. G. E. and Mulder, N. H. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. Int. J. Cancer, 53, 110-117 (1993).
26. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L. and Chaney, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54, 3500-3505 (1994).
27. Barret, J. M., Calsou, P., Larsen, A. K. and Salles, B. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Mol. Pharmacol., 46, 431-436 (1994).
28. Brown, G. A., McPherson, J. P., Gu, L., Hedley, D. W., Toso, R., Deuchars, K. L., Freedman, M. H. and Goldenberg, G. J. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res., 55, 78-82 (1995).